Oxford Nanopore Technologies (ONT) Fireside Chat summary

Introduction and agenda

• The session began with a recap of key trading statement highlights, followed by a detailed discussion of market drivers and a Q&A segment for audience questions.

Background and experience of the speaker

• The moderator has followed the company for nearly 15 years and leads a European healthcare equity research team.

Current industry trends

• Achieved 24% constant currency revenue growth, surpassing guidance, despite challenges in NIH funding, China, and tariffs.

• All regions saw over 20% growth, with the Americas up 30% in H2; clinical and biopharma segments grew 60% and 30%, respectively.

• Shifted to a CapEx sales model, improving cash flow by £20M and gross margin by 300-400 bps; now nearly 100% of device sales are CapEx.

• Inflationary and market-level price increases are now standard, in line with industry peers.